Appendix B. Sources of evidence considered by the Committee
A. The following manufacturer/sponsor provided a submission for this appraisal:
Biogen Idec UK and Elan Pharma International
B. The evidence review group (ERG) report for this appraisal was prepared by Peninsula Technology Assessment Group, University of Exeter:
Ruth Garside, Colin Green, Martin Hoyle, et al. The effectiveness and cost effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen, February 2007.
C. The following individuals were selected from clinical specialist and patient advocate nominations from the professional/specialist and patient/carer groups. They gave their expert personal view on natalizumab for the treatment of multiple sclerosis by providing written evidence to the Committee. They are invited to comment on the appraisal consultation document.
Professor David Miller, nominated as a clinical expert by the Association of British Neurologists
Professor Alan Thompson, nominated as a clinical expert by the Multiple Sclerosis Society
Megan Burgess, nominated as a clinical expert by the Royal College of Nursing
Mrs Caroline Haynes, nominated as a patient expert by the
Mr Mark Priest, nominated as a patient expert by the MS Trust